RESTASIS / RESTASIS MULTIDOSE — FDA application NDA050790
Listed sponsor: ABBVIE · ABBV company profile · exact_unique
Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.
FDA application facts
| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
|---|---|---|---|---|---|---|---|---|
| 001 | RESTASIS | CYCLOSPORINE | EMULSION | OPHTHALMIC | 0.05% | Prescription | AB | Yes |
| 002 | RESTASIS MULTIDOSE | CYCLOSPORINE | EMULSION | OPHTHALMIC | 0.05% | Prescription | not listed | Yes |
Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.
Orange Book patent and exclusivity listings
| Listing | Product | Descriptive date | Flags/code |
|---|---|---|---|
| Patent 8292129 | 002 | listed patent expiry date: 2031-02-25 | drug product |
| Patent 8561859 | 002 | listed patent expiry date: 2032-04-16 | drug product |
| Patent 9676525 | 002 | listed patent expiry date: 2034-02-07 | drug product |
| Patent 9669974 | 002 | listed patent expiry date: 2034-05-11 | drug product |
Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.
Compound cross-links
- CYCLOSPORINE · UNII 83HN0GTJ6D · lmmol compound PMATZTZNYRCHOR-CGLBZJNRSA-N · CHEMBL160
Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.
Related pages
Sponsor company · FDA-approved application index
Peer clusters: Large-cap biopharma
Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.
Regulatory listing data as published by FDA; not medical or investment advice.